Ferric Maltol
drugOn this page
Also known as AccruferFeraccruIron maltolMaltol ferricoMaltol ferriqueST-10ST10
Summary
Ferric Maltol (CHEMBL4298110) is an approved small molecule (ATC B03AB10); indicated across 2 conditions including iron deficiency anemia and anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: B03AB10
- Indications: 2 conditions
- Clinical trials: 9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298110 |
| Name | Ferric Maltol |
| Type | Small molecule |
| Max phase | 4 |
| ATC | B03AB10 |
Also known as: Accrufer, Ferric maltol, Feraccru, Iron maltol, Maltol ferrico, Maltol ferrique, ST-10, ST10, FERRIC MALTOL
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| iron deficiency anemia | 4 | MONDO:0001356 | HP:0001891 |
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 6 |
| PHASE4 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05456932 | PHASE4 | UNKNOWN | Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease |
| NCT01340872 | PHASE3 | COMPLETED | Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) |
| NCT01352221 | PHASE3 | COMPLETED | Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn’s Disease (AEGIS-2) |
| NCT02680756 | PHASE3 | COMPLETED | Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD |
| NCT02968368 | PHASE3 | COMPLETED | Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease |
| NCT05126901 | PHASE3 | COMPLETED | Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years |
| NCT05177484 | PHASE3 | COMPLETED | Perioperative Iron for Colorectal Cancer (PICoC Study) |
| NCT03181451 | PHASE1 | COMPLETED | Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency |
| NCT05985070 | Not specified | UNKNOWN | Evaluating the Effectiveness of Various Iron Salts in Oral Iron Therapy for Iron Deficiency and Anemia in Healthy Adults |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: iron deficiency anemia, anemia